Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about RELIEF THERAPEUTICS HOLDING AG
01/19Relief Therapeutics Partner NRX Expands US Access to COVID-19 Treatment Zyesami
MT
01/19Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Ac..
EQ
01/14Relief Therapeutics Responds To NRx Lawsuit Claims; Shares Down 10%
MT
01/14Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Rec..
EQ
01/13GLOBAL MARKETS LIVE : Tesco, Google, Microsoft, Adler, TPG...
01/13NRX Pharmaceuticals Sues Relief Therapeutics for Alleged Breach of COVID-19 Drug Collab..
MT
01/12Relief Therapeutics Refutes NeuroRx's Breach of Contract, Defamation Claims
MT
01/12Relief Comments on Lawsuit Filed Against It by NeuroRx
EQ
01/06Relief Therapeutics Partner NRx Seeks US FDA's Emergency Use OK for COVID-19 Drug
MT
01/06Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil..
EQ
01/05Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQ
01/04Relief Therapeutics Partner NRX Seeks Provisional US Patent For Stable Compositions Of ..
MT
01/04Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provis..
EQ
01/03Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPE..
EQ
2021Relief Partner NRx Seeks US FDA's Breakthrough Therapy Tag for COVID-19 Drug
MT
2021Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for A..
EQ
2021Relief Therapeutics To Get Swiss Patent For Drug-Induced Pneumonitis Therapy In 2022
MT
2021Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Applica..
EQ
2021Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for P..
CI
2021Relief Therapeutics Files Registration To Qualify For Nasdaq Listing
MT
2021Relief Therapeutics Files Registration Statement on Form 20-F with the U.S. Securities ..
EQ
2021Relief Partner NRx Says No New Safety Concerns Found in Late-Stage COVID-19 Therapy Tri..
MT
2021Relief Reports that U.S. Collaboration Partner Announces New, Favorable Safety Report f..
EQ
2021Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil
CI
2021Relief Therapeutics' Partner Secures Regulatory Path For COVID-19 Drug In Hungary
MT
2021Relief Reports that its U.S. Collaboration Partner has Agreed with Hungarian Health Off..
EQ
2021Relief Therapeutics Appoints Chief Medical Officer, Other Executives
MT
2021Relief Therapeutics Announces Executive Changes
EQ
2021Relief Therapeutics Announces Executive Changes
CI
2021Relief Therapeutics Partner NRx Says Zyesami Outperforms Remdesivir in Critical COVID-1..
MT
2021Relief Reports U.S. Collaboration Partner Identifies Significantly Higher Likelihood of..
EQ
2021Relief Therapeutics Joins InveniAI to Develop New Drug Candidates For Rare Diseases
MT
2021US FDA Denies Breakthrough Therapy Designation For Relief Therapeutics' COVID-19 Drug
MT
2021Relief Therapeutics and InveniAI Sign a Strategic Collaboration Agreement to Identify N..
EQ
2021RELIEF THERAPEUTICS Holding SA and InveniAI Sign A Strategic Collaboration Agreement to..
CI
2021Relief Reports that its U.S. Collaboration Partner has Announced the U.S. Food and Drug..
EQ
2021Relief Therapeutics to Start Trading on OTC Market in US
MT
2021Relief Therapeutics Launches Level 1 ADR Program in the United States
EQ
2021Relief Therapeutics' Partner Wins US FDA Nod for Commercial Scale Production of Zyesami
MT
2021Relief Therapeutics to Roll Out Phenylketonuria Drug, Potential Urea Cycle Disorders Tr..
MT
2021Relief Therapeutics Chief Commercial Officer to Exit by November-End
MT
2021Relief Therapeutics Holding AG Appoints Anthony M. Kim as Senior Vice President and Hea..
CI
2021GLOBAL MARKETS LIVE : Electronic Arts, Credit Suisse, Novartis, Merck, Tesla...
2021Relief Therapeutics Files For Level 1 American Depositary Receipt Program
MT
2021Relief Therapeutics Partner NRx Says No New Safety Concerns Found in COVID-19 Treatment..
MT
2021Relief Therapeutics Unit's Nasal Spray Trial Confirms Safety, Tolerability in COVID-19 ..
MT
2021Acer Therapeutics Inc. and Relief Therapeutics Holding SA Announce Issuance of U.S. Pat..
CI
2021Relief Therapeutics Partner Gets US Patent For Investigational Product Candidate ACER-0..
MT
2021RELIEF THERAPEUTICS : Unit Says Nexodyn Acid-Oxidizing Solution's Data Affirms Ulcer Treat..
MT
2021RELIEF THERAPEUTICS' : COVID-19 Drug Shows Effectiveness In Open-Label Study
MT
2021RELIEF THERAPEUTICS : Partner NRx Submits Revised New-Drug Module For COVID-19 Therapy; Sh..
MT
2021GLOBAL MARKETS LIVE : General Motors, Apple, Tesco, Sika, Fortescue...
2021ACER THERAPEUTICS : Gets Notice of Allowance of US Patent Application for Drug For Urea Cy..
MT
2021RELIEF THERAPEUTICS : Acer Therapeutics Secure Notice Of Allowance For US Patent Claims
MT
2021RELIEF THERAPEUTICS : Takes NeuroRx to Court for Breaching COVID-19 Treatment Deal
MT
2021Acer Up After FDA Accepts NDA for ACER-001 in Urea-Cycle Disorders
DJ
2021Top Midday Gainers
MT
2021ACER THERAPEUTICS : Receives FDA Acceptance for New-Drug Application to Treat Urea Cycle; ..
MT
2021Acer Says FDA Accepts NDA for ACER-001 in Urea-Cycle Disorders; Shares Up
DJ
2021RELIEF THERAPEUTICS : Acer Therapeutics, Relief Therapeutics' Urea Cycle Disorder Drug Acc..
MT
2021Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Dru..
CI
2021RELIEF THERAPEUTICS : Says Monitoring Board Finds No New Safety Concerns in Late-Stage Stu..
MT
2021RELIEF THERAPEUTICS : Unit's Leg Ulcer Drug Shows Effectiveness in Open-Label Trial
MT
2021RELIEF THERAPEUTICS : Reports that U.S. Collaboration Partner Announced Second Favorable S..
EQ
2021RELIEF THERAPEUTICS : Partner NRX Reports Improved Results From Comorbid COVID-19 patients..
MT
2021RELIEF THERAPEUTICS : 2021 Half-Year Report
PU
2021RELIEF THERAPEUTICS : Slips To H1 Loss On Higher Expenses
MT
2021Relief Therapeutics Holding AG Reports Earnings Results for the Half-Year Ended June 30..
CI
2021RELIEF THERAPEUTICS : Unit Reports Further Benefits Of Physiomimic Technology In Phenylket..
MT
2021RELIEF THERAPEUTICS HOLDING AG(SWX : RLF) added to S&P Global BMI Index
CI
2021GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...
2021RELIEF THERAPEUTICS : Considers Rolling Submission for COVID-19 Drug in UK
MT
2021RELIEF THERAPEUTICS Holding SA Provides Update on Regulatory Interactions in the United..
CI
2021GLOBAL MARKETS LIVE : Ryanair, Hyundai, Adecco, Goldman Sachs, JD.com...
2021RELIEF THERAPEUTICS : Rebuffs NeuroRx's Accusations Over Aviptadil Collaboration Deal
MT
1  2  3  4  5  6Next